Skip to main content
OpenTrials
Completed

NCT Number: NCT07840313

Prophylactic Desmopressin Before Native Kidney Biopsy in Severe Renal Impairment

This study evaluated whether giving desmopressin before a native kidney biopsy reduces bleeding complications in adults with severe renal impairment (eGFR <30 mL/min/1.73 m²). Patients undergoing kidney biopsy were enrolled sequentially into two groups: a non-desmopressin group and a desmopressin group. Patients were monitored for 24 hours after biopsy for bleeding complications, including perinephric hematoma, a decrease in hemoglobin, blood in the urine, need for blood transfusion, and other complications. The study also evaluated whether desmopressin was associated with adverse effects such as low blood sodium levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Renal Impairment Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sindh Institute of Urology and Transplantation (SIUT)

Karachi, Sindh, 74200, Pakistan

About this study

This prospective sequential cohort study evaluated the association between prophylactic intranasal desmopressin use and bleeding complications following native kidney biopsy in adults with severe renal impairment. The study was conducted at the Sindh Institute of Urology and Transplantation (SIUT), Karachi, from October 2024 to September 2025. Adults aged 18 years or older with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² who underwent native kidney biopsy for clinical indications were consecutively enrolled. Patients were sequentially enrolled into a non-desmopressin cohort from October 2024 to March 2025 and a desmopressin cohort from April 2025 to September 2025. All patients underwent ultrasound-guided kidney biopsy and were monitored clinically and by ultrasonography for 24 hours after the procedure. The study evaluated post-biopsy bleeding complications and safety outcomes, including perinephric hematoma, hemoglobin decline, gross hematuria, blood transfusion, invasive interventions, and changes in serum sodium.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 18 years or older who provided informed consent, had an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m², and underwent native kidney biopsy for a clinical indication, irrespective of dialysis status.

-

Exclusion criteria

Pregnant women, kidney transplant recipients, and patients with contraindications to kidney biopsy.

-

Treatment and study plan

desmopressin acetate

Drug

Prophylactic intranasal desmopressin acetate administered before native kidney biopsy in adults with severe renal impairment (eGFR <30 mL/min/1.73 m²). Patients were monitored for 24 hours after biopsy for bleeding complications and safety outcomes.

NO DESMOPRESSIN

Other

Primary outcomes

  1. Overall bleeding complications after native kidney biopsy

    Time frame: Within 24 hours after kidney biopsy

    Occurrence of any post-biopsy bleeding complication, including clinically relevant perinephric hematoma, hemoglobin decline ≥2 g/dL, persistent or clinically significant gross hematuria, or other clinically significant bleeding complications.

Secondary outcomes

  1. Perinephric hematoma >5 cm, Hemoglobin decline ≥2 g/dL, Blood transfusion requirement, Hyponatremia

    Time frame: Within 24 hours after kidney biopsy

    Assessment of post-biopsy bleeding and safety outcomes, including perinephric hematoma >5 cm, hemoglobin decline ≥2 g/dL, clinically significant gross hematuria, blood transfusion requirement, and other clinically significant post-biopsy complications.

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Sindh Institute of Urology and Transplantation

Other

Registry information

Official study title

Prophylactic Desmopressin and Bleeding Outcomes After Native Kidney Biopsy in Patients With Severe Renal Impairment: A Prospective Sequential Cohort Study

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Sep 25, 2026
Registry last updated
Sep 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.